F-18-AV-1451 PET Imaging in Three Patients with Probable Cerebral Amyloid Angiopathy by Kim, HJ et al.
Tau distribution in probable Cerebral Amyloid Angiopathy 
 
Hee Jin Kim,1 Hanna Cho, MD2, Young Kyoung Jang,1 Yeo Jin Kim,1 Jin San Lee,1 Juyoun 
Lee,1 Duk L. Na,1 Chul Hyoung Lyoo2, Sang Won Seo, 1   
 
1Departments of Neurology, Samsung Medical Center, Sungkyunkwan University School of 
Medicine, Seoul, Korea 
2Department of Neurology, Gangnam Severance Hospital, Yonsei University College of 
Medicine, Seoul, Korea 
 
Corresponding author: Sang Won Seo 
Department of Neurology, Sungkyunkwan University School of Medicine, Samsung Medical 
Center, 50 Ilwon-dong, Gangnam-gu, Seoul 135-710, Republic of Korea 
Tel.: +82-2-3410-1233, Fax: +82-2-3410-0052, E-mail sangwonseo@empal.com 
 
Running head: Tau distribution in probable CAA 
Number of words in abstract: 105 
Number of words in main text: 1,075  
Number of figures: 1 
Number of tables: 1 
 
 Acknowledgement: 
This study was supported by Basic Research Program through the National Research 
Foundation of South Korea(NRF) funded by the Ministry of Education (NRF-
2013R1A1A2065365), the Korean Healthcare Technology R&D Project, Ministry for Health 
and Welfare Affairs (HIC120713), a Korean Science and Engineering Foundation (KOSEF) 
NRL program grant funded by the Korean government (MEST; 20110028333), a Samsung 
Medical Center Clinical Research Development Program grant (CRL108011 & CRS 110-14-
1), the Korea Ministry of Environment (MOE) as the Environmental Health Action Program 
(2014001360002), and the National Research Foundation of Korea(NRF) grant funded by the 
Korea government(MSIP) (NRF-2015R1C1A2A01053281). 
 
Potential Conflicts of Interest: 
All authors report no disclosures.
Abstract 
Cerebrovascular deposition of amyloid-ß (cerebral amyloid angiopathy, CAA) is associated 
with magnetic resonance imaging findings of lobar hemorrhage, cerebral microbleeds, andor 
cortical superficial siderosis. Although pathological studies suggest that The aim was to 
evaluate the relationship between tau may co-localise with vascular amyloid, with relevance 
for understanding disease mechanisms, this has not yet been investigated in CAA in vivo. and 
tau in CAA patients. We therefore used Three patients with clinically diagnosed CAA 
underwent [11C]Pittsburgh Compound B PET or [18F] Florbetaben PET to measure amyloid 
burden, and [18F]T807 to measure paired helical filament tau in patients with probable CAA. 
The regions with  that had cerebral microbleeds or cortical superficial siderosis largely 
overlapped with those showing regions that showed iincreased [18F]T807 and uptake as well 
as increased [11C]PiB uptake. Our study This provides preliminary in vivo evidence that 
vascular amyloid is associated with local production of paired helical filament tau.  
Introduction 
Cerebral amyloid angiopathy (CAA) refers to a condition where ß-amyloid protein 
accumulates in the walls of small cortical and leptomeningeal arterioles and arterieses.1-3 
Although definite CAA can only be confirmed pathologically, the Boston criteria are a set of 
clinical radiological criteria allow the to diagnosis ofe CAA in a noninvasively with high 
specificity in patients with intracerebral haemorrahge  way(Knudsen paper ref). SRecent 
studies showed that strictly lobar microbleeds or cortical superficial siderosis (cSS) are also a 
radiologic marker of CAA in populations without intracerebral hemorrhage.4 Furthermore, 
previous studies show that cerebrovascularal amyloid can be detected by amyloid imaging 
studies using PiB-PET.5, 6  
Recent advances in in-vivo tau imaging have opened a new era in neurodegenerative 
disease research. The T807,  one of the tau tracer, binds to paired helical filament (PHF)-tau, 
and has provided valuable data on the distribution of tau in Alzheimer’s disease patients.7-9 
However, the distribution of tau and the relationship between vascular amyloid and tau in 
CAA patients has not been are unddefined. Previous reports suggest that have revealed that 
abnormally phosphorylated tau accumulates around beta-amyloid laden arteries more than 
exceeded that around non-beta amyloid laden blood vessels.10-12 WeTherefore, we tested the 
hypothesis that zed that CAA patients would have greater tau deposition in  the regions of  
where there is ggreater vascular amyloid burden using . Herein, we report 3 cases of 
clinically diagnosed CAA who underwent [18F]T807-PET and PiB-PET..  
 
Patients and Methods 
Subjects  
Among the patients who visited memory clinic at Samsung Medical Center, we 
recruited three patients who had strictly lobar MBs or cSS, indicating  which met cla inical 
diagnosis of probable CAA according to the Boston’s criteria (Table 1).4, 13-15 All three 
patients underwent neuropsychological tests using a standardized neuropsychological 
battery,16, 17 which showed that two patients (Case #1 and #2) had multiple domain amnestic 
MCI and one patient (Case #3) had amnestic- type of dementia.  
This study was approved by the Institutional Review Board of Samsung Medical 
Center. We obtained informed consent from all participants. 
Assessment of cerebral microbleeds and cortical superficial siderosis on MRI 
All the participants underwent brain MRI. T2, T2*, T1, FLAIR, and T2 Fast Field Echo 
(FFE) MR images were acquired at Samsung Medical Center using the same 3.0T MRI 
scanner (Philips 3.0T Achieva). Microbleeds were defined as homogenous round signal loss 
lesions (≤10mm in diameter) on T2*-weighted images.18 Strictly lobar microbleeds were was  
defined as having microbleeds restricted (exclusively) to a lobar locations. Cortical 
superficial siderosis was also defined as linear hypointensities on T2*-weighted images 
consistent chronic blood residues in the superficial layers of the cerebral cortex.19 
Amyloid PET acquisition and data analysis 
Case #2 and #3 underwent [11C]Pittsburg compound B (PiB) PET at Samsung 
Medical Center using a Discovery STe PET/CT scanner (GE Medical Systems, Milwaukee, 
WI, USA) in a 3-dimensional scanning mode that examined 35 slices of 4.25-mm thickness 
spanning the entire brain. [11C]PiB was injected into an antecubital vein as a bolus injection 
with a mean dose of 420 MBq (i.e., range 259–550 MBq). 60 minutes after injection, a CT 
scan was performed for attenuation correction. A 30-minute emission static PET scan was 
then initiated. Attenuation corrected PET images were reconstructed from the CT data using 
an iterative reconstruction method. The specific radioactivity of [11C]PiB at the time of 
administration was higher than 33.3 GBq/μmol for patients. In all PET studies, the 
radiochemical purity of the radiotracer was higher than 95%.  
Case #1 underwent [F18] Florbetaben PET at Samsung Medical Center using XXX 
scanner. The images were acquired at 90 minutes after the intravenous bolus injection of 
283.2 ± 31.3 MBq of 18F-florbetaben for 20 minutes. 
 
T-807 PET acquisition and data analysis 
All three patients underwent T807 PET at Gangnam Severance Hospital using a 
Biograph mCT PET/CT scanner (Siemens Medical Solutions; Malvern, PA, USA). We 
acquired amyloid and tau PET scans on separate days. Tau PET images were acquired for 20 
minutes, starting at 80 minutes after the intravenous bolus injection of 275.2 ± 28.0 MBq of 
18F-AV-1451. Prior to the PET scan, we applied a head holder to minimize head motion and 
also acquired brain computed tomography (CT) images for attenuation correction. Finally, 
using the ordered-subsets expectation maximization (OSEM) algorithm (iteration = 6 and 
subset =16), 3D PET images were reconstructed in a 256 × 256 × 223 matrix with a 1.591 
×1.591 × 1 mm voxel size. 
 
Results 
In all three patients, the regions with  that had CMBs or cSS largely overlapped with 
regions that showed increased [18F] T807 retention. The first case showed multiple CMBs in 
the left parietal and temporal areas, which and largely overlap with T807 uptake (Figure 1). 
Florbetaben PET was revealed to be negative by visual rating. The second case showed 
asymmetric multiple CMBs in the left temporal area, corresponding  which corresponds to 
the area of high PiB uptake. Asymmetric high T807 uptake was observed in the inferior 
temporal area, paralleling the area of CMB or cSS identified by T2* weighted images (Figure 
1). The third case showed asymmetric CMB or cSS in the right parietal, occipital, and 
temporal areas, also co-localising with  where high PiB uptake was seen. Although high 
T807 uptake was observed in the bilateral parietal, occipital, and temporal areas, there was 
preferential uptake on the asymmetry toward the right side, where CMBs or cSS were 
identified.  
   
Discussions 
We report the imaging findings of three patients cases wwith clinically probable CAA 
with ho had asymmetric distribution of strictly multiple lobar CMBs or cSS, indicating 
probable CAA: the first case had left hemispheric dominant distribution of CMB, while  and 
the other two second and third cases had a posterior  dominant distribution of CMBs. In 
each patient, Their [18F] T-807 PET showed increased T-807 uptakes in regions especially in 
neighboring regions where CMB or cSS were locateddistributed, providing the preliminary in 
vivo evidence that vascular amyloid might be co-localised with be associated with local 
production of paired helical filament PHF form of tau. 
 Our finding that clinical probable CAA had increased T-807 uptakes especially in the 
neighboring region where CMB or cSS were located is consistent with previous 
immunohistochemical studies showing tau immunopositive neurites clustered around cortical 
arteries with affected by amyloid angiopathy,.10, 11 suggesting that peri-vascular accumulation 
of hyperphosphorylated tau may result from elevated levels of soluble amyloid beta 1-40 
around cortical arteries and arterioles (ref 10). However, a recent in vitro study found showed 
that there was no autoradiographic binding of T807 in CAA or cSS lesions, containing 
hemosiderin deposits.20 This discrepancy might be related to differences in binding 
conditions (in vivo versus in vitro autoradiographic binding). Our hypothesis that lobar CMB 
or cSS (indicating CAA) are related to local accumulation or production of tau is supported 
by a CSF biomarker study showing that patients with clinically probable CAA had higher t-
tau and p-tau compared to controls.3 An alternative explanation is thatOur suggestion that 
lobar CMB or cSS are related to local production of tau is supported by a CSF biomarker 
study showing that clinical probable CAA patients had higher t-tau and p-tau compared to 
controls.3 It is possible that T807 may binds to hemosiderin deposits in the local hemorrhagic 
lesions, a. Although the regions of increased T807 uptakes did not exactly parallel overlap 
with the distribution of CMBs or cSS, they clearly showed tendency toward neighboring 
regions of CMB or cSS location. Finally, we cannot exclude the possibility that tau may exist 
in relation to rapidly progressive neurodegeneration, rather than being specifically related to 
CAA.21-24  
We noted that also found that the distribution s of PiB uptake in Case 2 and 3 was 
were different from typical pattern of amyloid distribution in AD, but rather largely 
overlapped with CMB or cSS lesions which were distributed in the posterior brain regions. 
Our findings are thus were consistent with previous studies showing a greater occipital-to-
global PiB ratio in probable CAA subjects compared to AD subjects.25, 26 By contrast,  
However, interestingly, there was noere no increase in florbetaben uptakes in the left 
hemisphere of case 1, where there were many CMBs; this . This might be due to difference in 
the amyloid tracer, or less . Alternatively, case 1 might not have advanced degree of CAA 
than the unlike other cases. Indeed, aA previous study showed that mild degree of CAA 
might not be associated with amyloid uptakes detected by in -vivo PET (Seo et al., AAIC 
2015). Further studies of amyloid PET imaging in various stages of CAA patients using 
differentvarious amyloid tracers are needed.  
Our study has limitations: we did not have The limitation of this study is lack of 
pathological confirmation of CAA, and the use of y data to confirm the clinical diagnosis and 
PET findings. In addition, different amyloid tracers might have affected the were used to in 
amyloid PET imaging which gave inconsistent results regarding relationships between 
amyloid and tau/CMB. Nevertheless, our findings provide new in vivo evidence that to our 
knowledge, this is the first study to evaluate T807 distribution in CAA patients. Our novel 
findings suggest that vascular amyloid might be associated with local production of paired 
helical filament PHF form of tau.
Table 1 Characteristics of clinically diagnosed CAA patients 
  Case #1 Case #2 Case #3 
Age 74 85 70 
Gender F M F 
Education 16 years 12 years 9 years 
APOE genotype e3/e4 e3/e4 e3/e4 
MMSE 20  23 14 
Lobar Microbleeds, n  82 14 5 
cSS, n[DW1] 0 2 1 
Lacunes, n 4 0 0 
WMH* moderate moderate moderate 
Medial temporal 
atrophy** 
G1/G3 G2/G2 G2/G1 
Amyloid PET 
[18F]Florbetaben 
negative 
[11C]PiB 
positive 
[11C]PiB 
positive 
Initial symptoms 
Word finding difficulty 
Memory impairment 
Word finding difficulty 
Memory impairment 
Visuospatial dysfunction 
Irritability 
Word finding difficulty 
Memory impairment 
Disease duration 5 years 6 years 5 years 
Cognitive test result 
Multiple domain amnestic 
MCI 
Multiple domain 
amnestic MCI 
Dementia 
Neurological 
examination 
Unremarkable Unremarkable Unremarkable 
*mild: periventricular white matter hyperintensities (WMH) < 5mm and deep WMH < 10mm 
 Moderate: between mild and severe 
 Severe: periventricular WMH ≥ 5mm and deep WMH≥ 10mm 
** graded by Schelten’s criteria (REF) 
 
Figure legends 
Figure 1. [18F]Florbetaben, [11C]Pittsburgh compound B (PiB), [18F]T807 PET, T2* weighted MRI, and FLAIR in probable CAA patients 
Colored areas for  [18F]Florbetaben or [18F]T807 PET represents SUVR ≥1.5 (ref: cerebellar gray matter).
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